Juargo schreef op 25 april 2019 18:01:
Mijn excuses als het hier al is gepost, maar best een interessant bericht in het light topic. Een trial van Gilead heeft endpoint niet gehaald, wat extra druk op de nieuwe CEO legt.
Cantor Fitzgerald: From our conversations, we think many investors see GLPG as a potential M&A candidate.
CITI analysts: Gilead "Without NASH, Gilead needs M&A to grow.
Company is looking, keeping Daniel O'Day informed.
In speaking with mgmt, the sense of urgency remains, they are actively looking.
With GLPG1690 recently entering twin Phase 3 trials to treat IPF, we see a high potential for it to become the standard-of-care if approved. GLPG1690 is wholly owned by Galapagos.
Announcement of new programs such as the Toledo compound will continue to expand GLPG’s pipeline and would also be a nice asseset for Gilead.
JPM we believe that this failure adds an increasing amount of pressure on Daniel O'Day to put his stamp on the company (in the form of M&A).
Extra druk dus bij Gilead om een overname te doen.